CHOP or THP‐COP regimens in the treatment of newly diagnosed peripheral T‐cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin

Abstract

The CHOP regimen consisting of cyclophosphamide, doxorubicin (DOX), vincristine and prednisolone has been the most used regimen for peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). Pirarubicin [tetrahydropyranyladriamycin (THP)], a derivative of DOX, is an anthracycline with reportedly less cardiotoxicity than DOX. Here, we confirmed the efficacy of THP-COP using THP instead of DOX in the treatment of PTCL-NOS. The study protocol employed a retrospective, consecutive entry design. We retrospectively analysed 56 patients with PTCL-NOS who had received THP-COP or CHOP. These regimens were performed every 21 days. Twenty-nine patients received THP-COP, and 27 received CHOP. There were no significant differences in known prognostic factors, including in the International Prognostic Index (IPI) and the prognostic index for T-cell lymphoma (PIT), between the two groups. Complete remission rates in patients with THP-COP and CHOP were 52% in both groups; the 3-year overall survival (OS) rates were 67% and 52% (p = 0.074), and the 3-year progression-free survival (PFS) rates were 51% and 29% (p = 0.070), respectively. In patients with low IPI (low or low-intermediate), THP-COP had significantly better 3-year OS (100% vs. 64%; p < 0.001) and 3-year PFS (75% vs. 33%; p < 0.05) than CHOP. Similar differences between THP-COP and CHOP were observed in patients with a low PIT (groups 1 or 2). Our study showed that THP-COP produced results equivalent to CHOP regarding efficacy and safety in patients with PTCL-NOS. In patients with low IPI or PIT, THP-COP resulted in significantly better prognosis. Copyright © 2015 John Wiley & Sons, Ltd.

Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

“…Reed-Sternberg cells stain positive for both PD-L1 and pSTAT3, suggesting an association between these two markers in lymphoma [ 18 ]. A few reports discovered association of PD-L1 and pSTAT3 expression in natural killer/T cell lymphoma [ 17 , 19 ], ALK-negative anaplastic large cell lymphoma [ 20 ] and cell lines of adult T cell leukemia/lymphoma [ 21 ]. In DLBCL, pSTAT3 is overexpressed, similar to PD-L1, in non-GCB subtype and shows higher expression than GCB subtypes [ 22 – 28 ].…”

Oxidative DNA Damage Induced by Pirarubicin, an Anthracycline Anticancer Agent, in the Presence of Copper(II)

“…Pirarubicin (4'-O-tetrahydropyranyl doxorubicin, THP; Figure 1A) is an anthracycline which was synthesized from doxorubicin ( Figure 1B) by Umezawa et al in 1979 (1). THP has a potent anticancer activity against a variety of solid cancer types as well as blood cancer (2,3). The cytotoxicity of THP against cultured tumor cells was found to be equal or superior compared to that of doxorubicin, and the cardiotoxicity of THP was less than that of doxorubicin in hamsters (4,5).…”

Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma

“…The 3-year overall survival was in favor of pirarubicin-CHOP, that is, 67% versus 52% for DOXO-CHOP. The 3-year progression-free survival for pirarubicin-CHOP was 75% versus 33% with DOXO-CHOP [19] . The 5-year survival rate with CHOP is only 19% in PCTL-NOS [20] .…”